Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome + Bevacizumab Maintenance in mCRC
NCT06341309Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2024
- Primary completion
- Apr 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of irinotecan liposome in metastatic colorectal cancer (mCRC), sponsored by West China Hospital of Sichuan University. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06341309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341309.